AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects
ABSTRACT CT014Credit: The University of Texas MD Anderson Cancer Center ABSTRACT CT014 SAN DIEGO – The first-in-class PARP1-selective inhibitor saruparib ...

